PTGS2 and neoplasm: Inhibition of COX-2 by celecoxib proved to be a promising pharmacological modulation as chemoprevention of urinary bladder carcinogenesis if used earlier in tumor growth, as preventive, but not if used as a curative or regressive therapy.